# Gene Biotherapeutics, Inc.

Gene Biotherapeutics, Inc. is a company headquartered in San Diego, CA, United States.

## Company overview

- **Legal name:** Gene Biotherapeutics, Inc.
- **Former names in filing history:** Taxus Cardium Pharmaceuticals Group Inc. (2014-03-18 to 2018-09-13); Cardium Therapeutics, Inc. (2005-05-31 to 2014-03-04); ARIES VENTURES INC (2000-06-19 to 2006-01-06); CASMYN CORP (1996-07-18 to 2000-05-09)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** San Diego, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000772320

## About

Gene Biotherapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000772320, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2022-03-30, it reported net income of USD -517,897; total assets of USD 566,982 for the fiscal period ended 2020-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2020 (period ended 2020-12-31)

- **Net income:** -$517,897 (USD -517,897)
- **Total assets:** $566,982 (USD 566,982)
- **Cash and equivalents:** $386,027 (USD 386,027)
- **Operating cash flow:** -$1.1M (USD -1,133,005)

### FY2019 (period ended 2019-12-31)

- **Net income:** $866,675 (USD 866,675)
- **Total assets:** $35,435 (USD 35,435)
- **Operating cash flow:** -$137,162 (USD -137,162)

### FY2016 (period ended 2016-12-31)

- **Net income:** -$2.9M (USD -2,918,228)
- **Total assets:** $1.1M (USD 1,110,817)
- **Cash and equivalents:** $930,397 (USD 930,397)

### FY2015 (period ended 2015-12-31)

- **Net income:** -$3.7M (USD -3,697,560)
- **Total assets:** $37,303 (USD 37,303)
- **Cash and equivalents:** $21,547 (USD 21,547)

## Recent SEC filings

- Form 10-K/A — filed 2022-04-14 — period 2020-12-31
- Form 10-K — filed 2022-03-30 — period 2020-12-31
- Form 10-Q — filed 2021-10-27 — period 2020-09-30
- Form 10-Q — filed 2021-09-17 — period 2020-06-30
- Form 10-Q — filed 2021-09-03 — period 2020-03-31
- Form 8-K — filed 2021-08-05 — period 2021-08-02
- Form 8-K — filed 2021-07-28 — period 2021-07-28
- Form SC 13G — filed 2021-04-28
- Form 8-K — filed 2021-04-26 — period 2021-04-26
- Form 10-K — filed 2021-04-23 — period 2019-12-31
- Form SC 13D — filed 2021-03-01
- Form SC 13G — filed 2020-12-22 — FORM SC 13G

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/gene-biotherapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology